Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.99+0.65 (+6.96%)
At close: 4:00PM EDT
8.56 -1.43 (-14.31%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close9.34
Open10.11
Bid8.34 x 1000
Ask8.55 x 2900
Day's Range9.86 - 10.40
52 Week Range4.95 - 10.80
Volume3,643,777
Avg. Volume472,309
Market Cap585.376M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.06
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.15
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVDL

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avadel Pharmaceuticals plc
    JAZZ: Raising target price to $149.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $149.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • GlobeNewswire

    Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

    DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October. The FDA informed the company that there are no information requests at this time and a new target action date will be provided as

  • TipRanks

    2 Healthcare Stocks With Big Catalysts in October

    Healthcare stocks have a reputation of keeping investors on their toes. The possibility of surging price action, or conversely, earth shattering drops is very real, but these movements can come and go in the blink of an eye. As a result, these stocks need constant monitoring ahead of key catalysts, as they can affect the price dramatically. Additionally, the price movement is usually dependent on one of the following: either a regulatory approval or trial data. Once either is announced to the pu

  • Zacks

    Implied Volatility Surging for Avadel (AVDL) Stock Options

    Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Advertisement
Advertisement